Theranexus SA
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonym… Read more
Theranexus SA - Asset Resilience Ratio
Theranexus SA (ALTHX) has an Asset Resilience Ratio of 66.62% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Theranexus SA's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Theranexus SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €1.51 Million | 33.31% |
| Short-term Investments | €1.51 Million | 33.31% |
| Total Liquid Assets | €3.02 Million | 66.62% |
Asset Resilience Insights
- Very High Liquidity: Theranexus SA maintains exceptional liquid asset reserves at 66.62% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Theranexus SA Industry Peers by Asset Resilience Ratio
Compare Theranexus SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Theranexus SA (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Theranexus SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 13.49% | €504.56K | €3.74 Million | -69.47pp |
| 2021-12-31 | 82.97% | €14.01 Million | €16.89 Million | +54.34pp |
| 2020-12-31 | 28.63% | €5.00 Million | €17.47 Million | -49.79pp |
| 2019-12-31 | 78.42% | €12.05 Million | €15.37 Million | -6.65pp |
| 2018-12-31 | 85.07% | €16.03 Million | €18.85 Million | +72.96pp |
| 2016-12-31 | 12.11% | €348.87K | €2.88 Million | -39.08pp |
| 2015-12-31 | 51.19% | €1.40 Million | €2.73 Million | -- |